Back to Authors

Graves, Jennifer

https://orcid.org/0000-0003-1539-1940

A5062645534 | I36258959

Mayo Clinic

University of California San Diego

Citations 51

Efficacy and safety of inebilizumab in patients aged 50 years and older with neuromyelitis optica spectrum disorder: N-MOmentum study subgroup analysis

Arquivos de Neuro-Psiquiatria | October 11, 2024 | Volume: 82 | Issue: S 01 | Pages: S1-S52

10.1055/s-0044-1789431

Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations

JAMA Neurology | September 16, 2024 | Volume: 81 | Issue: 11 | Pages: 1210

10.1001/jamaneurol.2024.3062 | PMID 39283621

Importance While the typical onset of multiple sclerosis (MS) occurs in early adulthood, 2% to 10% of cases initially present prior to age 18 years, and approximately 5% after age 50 years. Guidance on approaches to differential diagnosis in suspected MS specific to these 2 age groups is needed. Observations There are unique biological factors in children younger than 18 years and in adults older than age 50 years compared to typical adult-onset MS. These biological differences, particularly immunological and hormonal, may influence the clinical presentation of MS, resilience to neuronal injury, and differential diagnosis. While mimics of MS at the typical age at onset have been described, a comprehensive approach focused on the younger and older ends of the age spectrum has not been previously published. Conclusions and Relevance An international committee of MS experts in pediatric and adult MS was formed to provide consensus guidance on diagnostic approaches and key clinical and paraclinical red flags for non-MS diagnosis in children and older adults.
Predictors of a Relapsing Course in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (S7.008)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000208303

Patterns of Use and Safety of Newer Disease-modifying therapies in Pediatric Multiple Sclerosis in the US (S51.004)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s51.004

Distribution and predictors of disease severity in pediatric multiple sclerosisInvestigate the distribution of disease severity in pediatric-onset multiple sclerosis (MS). (S49.008)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s49.008

The Causal Effect of Serum Vitamin D Levels on Pediatric Multiple Sclerosis: A Mendelian Randomization Study (S29.007)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s29.007

Dietary Factors and Risk of Pediatric Multiple Sclerosis (S29.006)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s29.006

Demographic and Clinical Characteristics of 490 Children and Adolescents with Multiple Sclerosis (MS): US Network of Pediatric MS Centers’ Experience (S29.004)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s29.004

Effect of Obesity and Puberty on Risk and Age at Onset of Pediatric MS (S29.003)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s29.003

First Genome-Wide Analysis in Pediatric Multiple Sclerosis (MS) Confirms a Role for Adult MS Risk Variants and Reveals New Candidates (S29.001)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s29.001